GH Research: GH001 Shows Robust Data Ahead Of FDA IND Decision [Seeking Alpha]
GH Research PLC - Ordinary Shares (GHRS)
Company Research
Source: Seeking Alpha
GH001 demonstrated robust Phase 2b efficacy—a 15.5-point MADRS reduction at Day 8 and 73% six-month remission—with infrequent dosing and strong safety. GHRS maintains a disciplined cost structure, $293.9M in cash, and a projected runway exceeding five years at current burn rates. A positive IND outcome could catalyze further upside, but current valuation reflects significant optimism already priced in. Maskot/DigitalVision via Getty Images Thesis As many of you know, GH Research's ( GHRS pipeline is pretty much centred around their proprietary mebufotenin-based therapies for depression. Their lead candidate is, of course, GH001, which is an inhaled formulation for treatment-resistant depression. Now GH001 This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opi
Show less
Read more
Impact Snapshot
Event Time:
GHRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GHRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GHRS alerts
High impacting GH Research PLC - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
GHRS
News
- GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRDGlobeNewswire
- What Does GH Research PLC (GHRS)'s Clinical Progress Updates Say? [Yahoo! Finance]Yahoo! Finance
- GH Research FY25 Results: Strong Cash Position As GH001 Advances Toward Phase 3 [Seeking Alpha]Seeking Alpha
- GH Research (GHRS) was given a new $34.00 price target by Guggenheim.MarketBeat
- GH Research (GHRS) had its price target raised by Citizens Jmp from $39.00 to $42.00. They now have a "market outperform" rating on the stock.MarketBeat
GHRS
Earnings
- 3/5/26 - Miss
GHRS
Sec Filings
- 3/25/26 - Form 6-K
- 3/16/26 - Form 6-K
- 3/5/26 - Form S-8
- GHRS's page on the SEC website